Skip to main content
GNLX
NASDAQ Life Sciences

Q3 Loss Widens to $10.29M, Missing Consensus by $1.5M as Phase 3 Costs Climb

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.88
Mkt Cap
$86.871M
52W Low
$1.77
52W High
$5.89
52W Position info
6.2% above low
Off High info
68% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

GNLX is trading near its 52-week low of $1.77 (6.2% above the low).

Summary

Genelux posted a Q3 net loss of $10.29 million, or $0.23 per share, versus the $8.78 million consensus from five analysts — a clear miss. Operating expenses ran $10.40 million, driven by higher clinical and regulatory costs for the Phase 3 OnPrime/GOG-3076 ovarian cancer trial. This follows the Q2 print on August 13, when the loss widened to $9.5 million on the same trial spending, so the burn is accelerating quarter over quarter. Cash and investments are still expected to fund operations only into 1Q27, and the $100 million at-the-market program filed in March remains the likely funding lever if the runway shortens. The binary event is Phase 3 OnPrime topline data expected in 2H26, with additional lung cancer dose-escalation updates due by year-end 2026.

At the time of this announcement, GNLX was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86.9M. The 52-week trading range was $1.77 to $5.89. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

GNLX - Latest Insights

GNLX
Nov 16, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.88
Real-time Price: $1.88 info
Change: $0 (0%) info
Market Cap: $86.871M info
GNLX
Sep 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.52
Real-time Price: $1.88 info
Change: -$0.640 (-25%) info
Market Cap: $86.871M info
GNLX
Aug 13, 2026, 4:20 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.63
Real-time Price: $1.88 info
Change: -$0.750 (-29%) info
Market Cap: $86.871M info
GNLX
Aug 13, 2026, 1:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.75
Real-time Price: $1.88 info
Change: -$0.870 (-32%) info
Market Cap: $86.871M info
GNLX
May 07, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.83
Real-time Price: $1.88 info
Change: -$0.950 (-34%) info
Market Cap: $86.871M info